Capital Fund Management (CFM)
ACAD icon

Capital Fund Management (CFM)’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Fund Management (CFM)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,800
Closed -$262K – 1554
2021
Q3 		$262K Buy
+15,800
New +$305K ﹤0.01% 1462

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital Fund Management (CFM)'s ACAD Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 28,540 shares — an estimated $762K sold.

Capital Fund Management (CFM) first reported a position in ACAD in Q3 2019 and held it in 23 quarters. The position peaked at $14.9M in Q2 2024. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Capital Fund Management (CFM) reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 28,540 Acadia Pharmaceuticals shares in Q1 2026, an estimated $762K.
  • Capital Fund Management (CFM) first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 23 quarters.
  • Capital Fund Management (CFM)'s Acadia Pharmaceuticals position peaked at $14.9M in Q2 2024.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.